menu search

ALPMF / Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanley Securities Akinori Ueda - Goldman Sachs Securities Shinichiro Muraoka - Morgan Stanley MUFJ Securities Madoka Sato - Schroder Investment Management Kasumi Haruta - Credit Suisse Securities Shinya Tsuzuki - Mizuho Securities Hiromitsu Ikeda Thank you very much for your participation on this earning call for Q1 FY 2023 Financial Results Ended June 30, 2023. I am Ikeda, Head of Corporate Communications, serving as the moderator for today. Read More
Posted: Aug 6 2023, 22:42
Author Name: Seeking Alpha
Views: 092060

ALPMF News  

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, more_horizontal

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 6, 2023

Astellas Pharma Inc. (ALPMF) Q2 2023 Earnings Call Transcript

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, A more_horizontal

Iveric Bio stock surges on Astellas Pharma takeover deal

By Proactive Investors
May 1, 2023

Iveric Bio stock surges on Astellas Pharma takeover deal

Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in ca more_horizontal


Search within

Pages Search Results: